We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
-22.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$402M
AUM Growth
-$164M
(-29%)
Cap. Flow
+$47.9M
Cap. Flow
% of AUM
11.9%
Top 10 Holdings %
Top 10 Hldgs %
62.89%
Holding
86
New
14
Increased
17
Reduced
23
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$55.3M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$43M |
| 3 |
TG Therapeutics
TGTX
|
+$21.3M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$20.9M |
| 5 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$21.9M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$18.3M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$16M |
| 4 |
The Ensign Group
ENSG
|
+$14M |
| 5 |
Sanofi
SNY
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.24% |
| 2 | Miscellaneous | 5.59% |
| 3 | Communication Services | 2.07% |
| 4 | Financials | 0.11% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Sabra Healthcare REIT
SBRA
$5.27B
| – | – |
-76,054
| Closed | -$1.62M |
|
77
Sarepta Therapeutics
SRPT
$2.2B
| – | – |
-75,000
| Closed | -$9.68M |
|
|
78
CALL
TG Therapeutics
TGTX
$8.26B
| – | – |
-41,500
| Closed | -$461K |
|
|
79
Vertex Pharmaceuticals
VRTX
$137B
| – | – |
-73,009
| Closed | -$16M |
|
|
RCM
80
DELISTED
R1 RCM Inc. Common Stock
RCM
| – | – |
-416,726
| Closed | -$5.41M |
|
|
SPPI
81
PUT
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| – | – |
-275,600
| Closed | -$1M |
|
|
RDUS
82
CALL
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-5,600
| Closed | -$113K |
|
|
AKRX
83
DELISTED
Akorn Inc
AKRX
| – | – |
-40,242
| Closed | -$60.4K |
|
|
FTSV
84
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| – | – |
-11,795
| Closed | -$464K |
|
|
BOLD
85
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – |
-305,726
| Closed | -$18.3M |
|
|
MDCO
86
DELISTED
Medicines Co
MDCO
| – | – |
-114,358
| Closed | -$9.71M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q1 2020 Portfolio in Review
As of Q1 2020, Eversept Partners held 86 positions worth $402M, down 29% from $566M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Eversept Partners deployed $47.9M of net new capital in Q1 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was HCA Healthcare: 101,000 shares worth $9.07M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was GSK, an estimated $21.9M trimmed.
- Eversept Partners's largest Q1 2020 buy was HCA Healthcare: 101,000 shares worth $9.07M.
- Eversept Partners added most to Zogenix, Inc. in Q1 2020, an estimated $55.3M increase.
- Eversept Partners's biggest Q1 2020 reduction was GSK, cutting an estimated $21.9M.
- Eversept Partners fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $18.3M.
- Eversept Partners's ten largest holdings make up 63% of its $402M portfolio in Q1 2020.
- Eversept Partners opened 14 new positions and closed 25 in Q1 2020.
- Eversept Partners's portfolio value fell 29% quarter-over-quarter to $402M.
Based on Eversept Partners's 13F filing for Q1 2020, filed 13 May 2020.